2. F F (Disclaimer)
F F F F F F F F
F ˈ F F F " F F " F
F F F F F F F F F F
F F F F F ˈ F F
F F F F ˁ F F
F F F F F F F F F F ˈ
F F F F F F F F F F
ˈ F F F F F
F F F F ˈ F F F
F F F F ˈ F F F F
F F F F
F F F F F
F
e-mail : ed2547@fda.moph.go.th F F
ISBN : 978-974-244-276-7
F : F
F 1 : 15,000 F 2552
F 2 : 3,200 F 2552
F : F F F
F F F F F 1
Thai National Formulary 2008 Volume 1 Gastro-intestinal system
11. - 7
F
1
(1) . .
(2) .
F F
(1) . F F
(2) . F
(3) . F F F
2
(1) . .
(2) . F
(3) . . F
(4) .
(5) . F
(6) . . F
3
(1) . . . F F ˅
(2) . ˆ
(3) . .
(4) . F
(5) .
F
4
(1) . .
(2) .
(3) . . F
(4) . . F
(5) . . F
(6) . . F
(7) . .
(8) . .
(9) . . F F F F
(10) . . F
(11) . . .
(12) . F F
(13) . F
(14) .
(15) .
1
F F F F
F F F F F
2
F F F F
F F ˈ F F F F F
3
F 17 F F F F F ˈ
4
F F F
F ˈ F F F
25. - 3
F F F F
10 F ˈ F
" F F "
F
F ˈ
(keyword) F ˈ F F
F F F F
F F F ˈ
F F F F
F F F F F
F F
F F ˈ F
F F
F F F F F
F ˈ F
F F F " F F
F F
" " F
ˈ F
F
F
F ˆ F ( F )
" F F F " F
F (rational drug therapy)"
F " F F (sufficiency
prescription)"
F F
F F
F ˈ F F 10 F F ˈ
F F F
F 10
F
F
F F (indication)
F ˈ
(efficacy)
ˈ F F F ˁ F F
(risk)
F ˁ ˈ
F F F (cost)
F F F F
F ˈ (other consi-
derations)
F
F F ˈ
(dose)
F (method of administration)
F (frequency of dose)
F F
1
2
3
4
5
6
7
8
28. - 6
F F F
F F F F F F F F
ˈ F F F F F
F F
2.1 F
F F
F F
F F ˈ F F F
ˈ F F F
F F F F
F
F 14
F F
(rheumatoid arthritis)
F F (osteoarthritis)
F (spondylosis) F F F
F F ˈ F F F
F F F (
F F kinin F F )
2
F F F ˈ
F F F F F
2
2.1 F
2.2 F F
2.3 F F F F
2.4 ˈ F
2.5 ˈ F F ˂
F F
2.6 ˈ F F F
F F F F
2 (EFFICACY)F orphenadrine ( F ) F
F F F F
F ˈ F F
F F12
( Beers Criteria F
F F -55) • F F
F docetaxel ( 2) imatinib ( 2) intravenous
immunoglobulin ( 2) liposomal amphotericin B
( 2) F ˁ F (terminally ill patient) (
F F ˁ F F -48)
F F F ˈ F F
F F ˁ F F
ˈ F F F 13
F ˈ F
• F F F F ˈ
F ˈ F F F F